All News

ACR guidance

ACR Updated Guideline on Vaccinations for Rheumatic Patients

d Jack Cush, MD

The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).

Read Article
CV,risk,MI,heart,cardiac

Gout Flares Up Cardiac Risks

d Jack Cush, MD

A large case-control study showed that gout patients who experienced a cardiovascular (CV) event were more likely to have had a recent (< 120 days) gout flare compared to those without CV events.

Read Article
RA erosions bone ACR

The Approach to Difficult to Treat Rheumatoid Arthritis

d Jack Cush, MD

Tan and Buch have reviewed the approach to difficult to treat rheumatoid arthritis (D2T-RA), with a new EULAR definiation of D2T-RA to foster an approach rationale and concideration of treatment options.

Read Article
hip,fracture3

Supplemental Vitamin D Fails to Lower Fracture Risk

d Jack Cush, MD

NEJM has published study results showing that vitamin D3 supplementation does not significantly lower fracture risk (vs. placebo) when used in generally healthy adults.

Read Article
knee,pain3,target

Krill Oil Effective in Knee Osteoarthritis

d Jack Cush, MD

Krill oil supplements in knee osteoarthritis (OA) was shown to be superior to placebo in reducing knee pain, stiffness and function while increasing the omega-3 index.

Read Article
DLE discoid lupus

Plasmacytoid Dendritic Cell Inhibitor in Cutaneous Lupus

d Jack Cush, MD

Litifilimab, a humanized monoclonal antibody against BDCA2, targets the BDCA2 receptor on plasmacytoid dendritic cells. When administered to patients with cutaneous lupus erythematosus (CLE) was shown reducing disease activity in CLE patients.

Read Article
Study of 57 #RA pts. w/ ILD treated with abatacept. Lung progression in 46% before ABA. After median 27 mos of follow-up, ILD - 72% improved or stabilized - 23% worsened - 5% died. No significant change in FVC, DLCO ILD worse assoc w/ DAS28, FVC DLCO https://t.co/7H87cAJRbG https://t.co/D60QFfevpA

Links:

Dr. John Cush RheumNow ( View Tweet)
New Updated GRAPPA Psoriatic Arthritis Recommendations The GRAPPA treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains." https://t.co/PkDofio1eh https://t.co/kp6UEgwonV

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA overview of Patient Reported Outcomes (PROs) - how generated, validated, used and limitations.https://t.co/572KxUO59s https://t.co/5c6xQfZqzu

Links:

Dr. John Cush RheumNow ( View Tweet)
Krill Oil Effective in Knee Osteoarthritis Krill oil supplements in knee OA was shown to be superior to placebo in reducing knee pain, stiffness and function while increasing the omega-3 index. https://t.co/JkLrz5C0Pk https://t.co/XzZWXJ8zgA

Links:

Dr. John Cush RheumNow ( View Tweet)
Plasmacytoid Dendritic Cell Inhibitor in Cutaneous Lupus Litifilimab, a humanized monoclonal antibody against BDCA2, targets the BDCA2 receptor on plasmacytoid dendritic cells. https://t.co/qOu2jMa6EK https://t.co/LMaY7gpt05

Links:

Dr. John Cush RheumNow ( View Tweet)
102 #RA patients in low dz activity followed for a year - half usual care vs half using smartphone assisted Pt-initiated care. DAS28 slightly increased in both groups without signif difference; app group had less visits (1.7 v 2.8; p<0.001) https://t.co/txttFjjgla https://t.co/TideQ5tVjJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Upadacitinib in non-radiographic Axial Spondyloarthritis The janus kinase inhibitor, upadacitinib, has been shown to significantly improve the signs and symptoms of nr-AxSpA, extending the efficacy of UPA beyond classic ankylosing spondylitis. https://t.co/BbvOSRxbXU https://t.co/z5QOaFKrxz

Links:

Dr. John Cush RheumNow ( View Tweet)
In the RECOVERY trial - 8156 hospitalized COVID-19 patients; those on baricitinib had significantly fewer deaths (12% vs 14% PBO) but the size of benefit was somewhat smaller than that suggested by previous trials. (adjusted rate ratio 0·87) https://t.co/EW7xLc9TLC https://t.co/Ahr7bwAQmJ

Links:

Dr. John Cush RheumNow ( View Tweet)
Risk of incident & recurrent H.Zoster higher after tofacitinib - Korean claims analysis of 11,720 seropos. RA pts Rx w/ bDMARD or tofacitinib (2011-19). 14% got HZ. Compared to other biologics (ABA), Tofa incr HZ (HR 2.5) & recurrence (HR 3.69) https://t.co/lDuqdtkIjR https://t.co/zJ3ArS3gGs

Links:

Dr. John Cush RheumNow ( View Tweet)
"He who has a strong enough why; can bear almost any how" - Friedrich Nietzsche https://t.co/BOpO9MMijR
Dr. John Cush RheumNow ( View Tweet)
Upadacitinib (Rinvoq) Approved by European Commission for use in adults with active Non-Radiographic Axial Spondyloarthritis - 15 mg qd p.o. Approval based on Phase 3 SELECT-AXIS 2 nr-axSpA trial published in Lancet https://t.co/n3Pci5GyoA https://t.co/4aoSOc7xHd

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic- Still's (or Not): Fever, Joint pain & Itchy Eyes 30 yr. woman with high fevers, itchy eyes and Still's manifestations for 6 weeks. Still's or Not? https://t.co/kbzhCxYp7H https://t.co/FEUzdXxHoW

Links:

Dr. John Cush RheumNow ( View Tweet)
Not Still’s – Now What? Your patient doesn't meet criteria for Still’s disease (AOSD or sJIA), now what should you do or consider? https://t.co/xPXZVzTXJr https://t.co/7hmhXFh6O3

Links:

Dr. John Cush RheumNow ( View Tweet)
Approach to ILD in Myositis Syndromes Mehta et al have published a full read review of managing ILD in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk. https://t.co/MLBGL2ZqTk https://t.co/cdO2nHAK6h

Links:

Dr. John Cush RheumNow ( View Tweet)
×